Egalet (EGLT) Earns Coverage Optimism Rating of 0.12

News stories about Egalet (NASDAQ:EGLT) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Egalet earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 44.0989257736704 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Egalet (NASDAQ:EGLT) remained flat at $$1.05 on Tuesday. 501,671 shares of the stock traded hands, compared to its average volume of 1,873,960. The company has a current ratio of 2.73, a quick ratio of 2.68 and a debt-to-equity ratio of -3.43. The firm has a market cap of $45.18, a PE ratio of -0.31 and a beta of 0.44. Egalet has a one year low of $0.80 and a one year high of $10.00.

EGLT has been the subject of several recent research reports. Cantor Fitzgerald set a $7.00 price objective on Egalet and gave the company a “buy” rating in a research note on Thursday, November 16th. Gabelli cut Egalet from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Stifel Nicolaus cut Egalet from a “buy” rating to a “hold” rating and set a $1.50 price objective for the company. in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $6.20.

TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2018/01/09/egalet-eglt-earns-coverage-optimism-rating-of-0-12.html.

About Egalet

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Insider Buying and Selling by Quarter for Egalet (NASDAQ:EGLT)

Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply